MedCap AB (61MA) Stock Price & Analysis
61MA Stock Chart & Stats
- Day’s Range
- EUR 48.54 - EUR 50.05
- 52-Week Range
- EUR 41.20 - EUR 56.60
- Previous Close
- EUR 48.48
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 760.84M
- Enterprise Value
- EUR 8.01B
- Total Cash (Recent Filing)
- EUR 272.80M
- Total Debt (Recent Filing)
- EUR 437.70M
- Price to Earnings (P/E)
- 30.3
- Beta
- 0.28
- Next Earnings
- Feb 05, 2027 (Est.)
- EPS Estimate
- 0.51
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Profitable Revenue Growth
Positive revenue expansion alongside healthy EBIT, EBITDA, and net margins indicates that MedCap’s portfolio companies are converting growth into substantial operating profitability. This supports reinvestment, strengthens the earnings base, and suggests the group has durable economic value beyond short-term sales fluctuations.
Sound Balance Sheet And Returns
Moderate leverage and expanding equity provide financial flexibility for portfolio development while limiting balance-sheet strain. Consistently strong ROE also indicates effective use of invested capital, supporting MedCap’s ability to compound value through its healthcare holdings over multiple periods.
Strong Free Cash Flow Quality
Free cash flow that broadly tracks net income provides evidence that reported earnings are translating into usable cash. Positive free cash flow growth can fund acquisitions, operating improvements, or other portfolio investments internally, reducing reliance on external financing for continued expansion.
Bears Say
Uneven Operating Cash Conversion
Although free cash flow is generally good, weaker and uneven operating cash conversion means earnings may not consistently arrive as cash within the same periods. This can create working-capital volatility, complicate portfolio funding decisions, and reduce flexibility during periods of faster investment or weaker trading.
Gross Margin Volatility
Significant changes in gross margin raise questions about the consistency of product mix, pricing, or cost structure across MedCap’s operating businesses. If this variability persists, it could make group-level profitability less predictable and reduce confidence that current margins represent a stable earnings base.
Leverage Requires Discipline
Current leverage is moderate rather than excessive, but its historical fluctuation means balance-sheet strength depends on continued capital discipline. Higher borrowing through a weaker cycle could constrain acquisitions, increase financing sensitivity, and leave less flexibility to support portfolio companies when conditions deteriorate.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
What is MedCap AB’s market cap?
When is MedCap AB’s upcoming earnings report date?
How were MedCap AB’s earnings last quarter?
Is MedCap AB overvalued?
Does MedCap AB pay dividends?
What is MedCap AB’s EPS estimate?
How many shares outstanding does MedCap AB have?
What happened to MedCap AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of MedCap AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
MedCap AB
MedCap AB (publ) operates as a private equity firm, employing a diverse array of investment strategies including secondary direct deals, later-stage funding, industry consolidation, growth capital provision, engagement with middle-market and mature businesses, turnarounds, and outright buyouts. The company primarily directs its capital towards businesses within the healthcare sector, focusing on medical equipment and services, biotechnology, life sciences, and pharmaceuticals. It actively seeks unlisted, small to mid-sized companies located predominantly across Northern Europe. Equity investments typically fall within the SEK 25 million to SEK 150 million range (approximately $2.75 million to $16.51 million). Target companies generally exhibit an enterprise value and annual sales revenue between SEK 50 million and SEK 200 million ($5.90 million to $23.06 million), alongside an EBITDA of SEK 1 million to SEK 50 million ($0.11 million to $5.50 million). MedCap aims to acquire ownership stakes of 20% to 50% in its portfolio entities, financing these through its own capital, loans, and direct balance sheet investments. Established in 2001, the firm maintains its headquarters in Stockholm, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Anders Dahlberg
- Employees
- 647
- Website
- www.medcap.se
- Address
- Engelbrektsgatan 9, Stockholm, AB, 114 32, SE
MedCap AB (61MA) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 15 | 6 | 1 |
| Technical Analysis | 3 | 6 | 1 |
| Moving Averages | 12 | 0 | 0 |
